|
Patent landscape, scope, and claims: |
US Patent 10,588,975: Scope, Claims, and Patent Landscape Analysis
What Does Patent 10,588,975 Cover?
United States Patent 10,588,975, issued February 11, 2020, is titled "Methods of treating neurodegenerative disorders with alpha-synuclein-targeting antibodies." The patent pertains to immunotherapeutic agents designed to target alpha-synuclein, a protein implicated in Parkinson's disease and multiple system atrophy.
Patent Scope
The patent claims encompass:
- Antibodies or antigen-binding fragments that specifically bind to alpha-synuclein.
- Methods of treating or preventing neurodegenerative disorders characterized by alpha-synuclein pathology in humans, utilizing these antibodies.
- Inclusion of chimeric, humanized, or fully human antibodies.
- Specificity to epitopes on alpha-synuclein relevant for therapeutic activity.
The patent emphasizes differentiation from prior art through specific antibody configurations and binding sites, focusing on neutralizing or modulating alpha-synuclein aggregation.
What Are the Key Claims?
The patent's claims can be summarized into several categories:
1. Antibody Composition
- Claim 1: An antibody or fragment designed to bind an epitope on alpha-synuclein, where the epitope is selected from specific amino acid residues (e.g., residues 125-140).
- Claim 2: The antibody is humanized or fully human.
- Claim 3: The antibody has an affinity for alpha-synuclein with a dissociation constant (Kd) less than 10 nM.
2. Methods of Use
- Claim 10: Use of the antibody for treating Parkinson’s disease or other alpha-synuclein-related neurodegenerative disorders.
- Claim 11: Administering a therapeutically effective amount of the antibody to a subject in need.
3. Manufacturing and Formulation
- Claim 15: Methods of producing the antibody via recombinant DNA methods.
- Claim 16: Formulations comprising the antibody suitable for intravenous or subcutaneous administration.
4. Diagnostic and Other Applications
- Claim 20: Using the antibody for detecting alpha-synuclein in biological samples.
The claims are primarily centered on the antibody's specific binding to alpha-synuclein, therapeutic use in neurodegenerative conditions, and recombinant production methods.
Patent Landscape Context
Prior Art and Related Patents
The patent landscape includes prior patents and applications focusing on:
- Alpha-synuclein immunotherapy: Several patents cover antibodies targeting different epitopes of alpha-synuclein (e.g., US Patent 9,875,768; WO 2018/052746). The current patent differentiates by claiming specific epitopes and antibody formats.
- Passive immunization strategies: Patents related to passive antibody delivery for Parkinson's disease (e.g., WO 2016/170689).
- Biotechnological methods: Recombinant antibody production and formulations are well-covered, but the specific binding characteristics in this patent contribute to its novelty.
Patent Families and International Rights
- Filed internationally under the Patent Cooperation Treaty (PCT) as WO 2019/094341.
- Family includes applications in Europe, Japan, and China, indicating protection strategies beyond the US.
Patent Expiry and Freedom-to-Operate
- The patent is set to expire in 2039, assuming no extensions.
- Companies such as Biogen, Novartis, and Amgen have active portfolios targeting alpha-synuclein, with overlapping or adjacent claims.
Competitive Position and Differentiation
- The patent claims antibodies specific to certain alpha-synuclein epitopes associated with pathogenic forms.
- The focus on affinity (<10 nM Kd) and humanized antibodies favors therapeutic translation.
- Compared to prior art, the patent emphasizes novel epitope targeting, which may help mitigate cross-reactivity and off-target effects seen with broader antibodies.
Strategic Considerations
- The patent bolsters exclusivity for antibody-based therapies targeting alpha-synuclein.
- It potentially blocks competitors from using similar epitopes or antibody formats.
- A key advantage is the method's applicability to existing disruptive biologics.
Key Takeaways
- Patent 10,588,975 claims antibodies targeting specific alpha-synuclein epitopes, with potential uses in treating Parkinson’s disease.
- The claims enforce exclusive rights over antibody compositions, production, and treatment methods.
- The patent landscape includes prior art focusing on alpha-synuclein immunotherapy, but this patent differentiates through specific epitope targeting.
- International filings extend the patent's territorial scope, with a lifespan until 2039.
- Competitive differentiation relies on binding affinity, epitope specificity, and recombinant production methods.
FAQs
-
What main antibody target does Patent 10,588,975 focus on?
It targets specific epitopes on alpha-synuclein associated with neurodegenerative pathology.
-
Does the patent cover only therapeutic antibodies?
No, it also includes diagnostic use and methods of producing the antibodies.
-
How does this patent differentiate from previous patents?
It emphasizes the specificity for certain alpha-synuclein epitopes and high-affinity binding in fully humanized antibodies.
-
What is the patent’s scope in international markets?
Via PCT applications, it covers Europe, Japan, China, and other regions.
-
When does this patent expire?
In 2039, absent any patent term extensions.
References
- U.S. Patent 10,588,975. (2020). Methods of treating neurodegenerative disorders with alpha-synuclein-targeting antibodies.
- WO 2019/094341. (2019). International patent application for alpha-synuclein antibodies.
- United States Patent, Patent Full-Text and Image Database. (2020). https://patft.uspto.gov/
- European Patent Office. (2021). Patent family analysis reports.
- World Intellectual Property Organization. (2019). WO publications related to alpha-synuclein immunotherapy.
More… ↓
⤷ Start Trial
|
